[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"autoantibodies\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:autoantibodies":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,56,85],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":28,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100631644","standardized-italian-network-enrolling-individuals-with-islet-autoantibodies-100631644",false,"NCT07503366","Standardized Italian netwoRk Enrolling iNdividuals With Islet-Autoantibodies","Standardized Italian netwoRk Enrolling iNdividuals With Islet-Autoantibodies (SIRENA)","SIRENA","Inclusion Criteria:\n\n* Individuals of any age who test positive for at least one islet autoantibody.\n* Absence of clinical symptoms of diabetes.\n* Do not meet ADA diagnostic criteria for diabetes (no overt hyperglycemia).\n* Ability to comply with follow-up procedures according to clinical practice.\n* Written informed consent obtained from the participant or, for minors, from a parent or legal guardian.\n\nExclusion Criteria:\n\n* Prior diagnosis of type 1 or type 2 diabetes.\n* Fasting plasma glucose ≥126 mg\u002FdL, HbA1c ≥6.5%, or OGTT 2-hour glucose ≥200 mg\u002FdL.\n* Presence of symptoms suggestive of diabetes (e.g., polyuria, polydipsia, unexplained weight loss, fatigue, visual disturbances, acetone breath, Kussmaul respiration).\n* Any medical or psychological condition judged by the investigator to interfere with study participation or data reliability.\n* Inability or unwillingness to provide informed consent.","ALL",{"count":19,"type":20},300,"ESTIMATED","OBSERVATIONAL","This project characterizes the longitudinal progression of children and adults who have tested positive for one or more islet cell autoantibodies across the early stages of type 1 diabetes (T1D). Despite advances in screening, limited evidence exists on how clinical, metabolic, and immunological markers evolve over time and predict progression to symptomatic disease. Using a screened cohort, participants are followed for up to 10 years with repeated standardized assessments. The study evaluates whether population-based screening can reduce diabetic ketoacidosis (DKA) at diagnosis and identify early predictors of progression to clinical T1D. Results are expected to improve risk stratification, inform surveillance strategies, and guide the timing of preventive interventions, with implications for clinical practice and health policy.",[24,25,26,27],"Type 1 Diabetes (T1D)","Autoantibodies","Hyperglycemia","Impaired Glucose Tolerance (Prediabetes)",[29,25,30,31,26,32,33,34,35,36,37,38,39,40,41,42],"Diabetes Mellitus, Type 1","Islets of Langerhans","Autoimmune Diseases","Impaired Glucose Tolerance","C-Peptide","Oral Glucose Tolerance Test","Continuous Glucose Monitoring","Psychological Stress","Early Diagnosis","Disease Progression","Presymptomatic Type 1 Diabetes","Type 1 Diabetes Stage 1","Type 1 Diabetes Stage 2","Type 1 Diabetes Stage 3","NOT_YET_RECRUITING","2026-04-02",{"date":46,"type":47},"2026-04-08","ACTUAL",{"date":49,"type":20},"2026-05",{"date":51,"type":20},"2036-04",{"name":53,"class":54},"Società Italiana di Endocrinologia e Diabetologia Pediatrica","OTHER",24,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":4,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":17,"minAge":63,"maxAge":4,"enrollmentInfo":64,"targetDuration":4,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":84},"100438792","phase-2-avatrombopag-in-the-treatment-of-adult-immune-thrombocytopenia-with-autoantibodies-100438792","NCT04993885","Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies","Efficacy and Safety of Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies Fail to Eltrombopag or Herombopag Treatment: a Single-center, Prospective, One-arm Clinical Trial","Inclusion Criteria:\n\n* The patients have provided written informed consent prior to enrollment.\n* Men and women greater than or equal to 18 years of age.\n* Diagnosed as ITP secondary to connective tissue diseases (including but not limited to systemic lupus erythematosus, Sjogren's syndrome and rheumatoid arthritis), primary ITP with positive antinuclear antibody but not up to the diagnostic criteria of connective tissue diseases, primary Evans syndrome, Evans syndrome secondary to connective tissue diseases, and primary ITP with positive Coomb's test but not up to the diagnostic criteria of Evans syndrome.\n* Platelet count\\\u003C30 ×10\\^9\u002FL at screening.\n* Patients who have previously failed to receive Eltrombopag or Herombopag \\[poor efficacy (Eltrombopag 75 mg\u002Fd or Herombopag 7.5 mg\u002FD, at least 4 weeks), or the efficacy cannot be maintained\\], or who have contraindications, can not tolerate or refuse Eltrombopag or Herombopag treatment.\n* Treatment for ITP (including but not limited to glucocorticoids, recombinant human thrombopoietin, and other thrombopoietin receptor agonists other than Avatrombopag) must be completed before enrollment, or the dose must be stable or in a phase of reduction within 2 weeks before enrollment.\n* Effective contraceptive measures will be taken during the clinical trial.\n\nExclusion Criteria:\n\n* Patients with active thyroid disease requiring treatment.\n* Patients with any prior history of arterial or venous thrombosis within 3 months, and with any of the following risk factors: cancer, Factor V Leiden, ATIII deficiency, or patients who are using anticoagulants or antiplatelet drugs at the beginning of screening.\n* Those who had received rituximab within 3 months.\n* Patients who had failed to respond to the previous use of Avatrombopag (40mg once a day for more than 4 weeks).\n* Subjects known to be allergic to Avatrombopag or any of its excipients.\n* Patients who had received splenectomy within 3 months or have splenectomy plan within 3 months.\n* Patients with lupus encephalopathy or lupus nephritis.\n* Patients with cataract.\n* Patients with infectious fever (including but not limited to pulmonary infection) within 1 month or with active infection during screening.\n* Existing hepatitis B virus, hepatitis C virus replication or HIV infection.\n* Severe liver dysfunction (alanine aminotransferase or glutamic oxaloacetic transaminase \\> 3×ULN).\n* Patients with severe cardiac or pulmonary dysfunction.\n* Severe renal damage (creatinine clearance \\\u003C 30 ml\u002Fmin).\n* There are surgical planners during the study.\n* History of psychiatric disorder.\n* Pregnant or lactating women or those planning to be pregnant during the trial.\n* Patients with a history of drug\u002Falcohol abuse (within 2 years before the study).\n* Patients that had participated in other experimental researches within one month before enrollment.\n* Any other circumstances that the investigator considers that the patient is not suitable to participate in the trial.","18 Years",{"count":65,"type":20},52,"INTERVENTIONAL",[68],"PHASE2","This prospective, open-label, single-center, one-arm clinical trial aims at evaluating the efficacy and safety of avatrombopag in Chinese adult Immune Thrombocytopenia (ITP) patients with autoantibodies fail (due to intolerance or resistance) to eltrombopag or herombopag treatment.",[71,25,72,73],"Immune Thrombocytopenia","Evan Syndrome","Connective Tissue Diseases","RECRUITING","2025-02-20",{"date":77,"type":47},"2025-02-24",{"date":79,"type":47},"2021-09-01",{"date":81,"type":20},"2025-09-30",{"name":83,"class":54},"Institute of Hematology & Blood Diseases Hospital, China",1,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":93,"sex":17,"minAge":63,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":96,"conditions":97,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":84},"100561799","follow-up-study-of-individuals-with-autoantibodies-against-rossa-and-lassb-100561799","NCT06594861","Follow-up Study of Individuals with Autoantibodies Against Ro\u002FSSA and La\u002FSSB","Follow-up of Clinical Manifestations and Inflammation-related Parameters in Individuals with Autoantibodies Against Ro\u002FSSA and La\u002FSSB","ProgreSS","Inclusion Criteria:\n\nTo be included in the risk group, the following criteria must be met:\n\n\\- At least one instance of testing positive for Ro\u002FSSA or La\u002FSSB, regardless of the method used.\n\nTo be included in the control group, the individual must:\n\n\\- Have no rheumatologic disease and no autoantibodies against Ro\u002FSSA or La\u002FSSB.\n\nExclusion Criteria:\n\n1. Below 18 years of age\n2. Inability to consent to their own participation\n3. Ongoing infection or severe illness where the study physician deems participation in the study not to be in the individuals best interest\n4. Inability to read and understand Swedish, and therefore unable to complete the forms and questionnaires included in the project",true,{"count":95,"type":20},500,"In this study, individuals with autoantibodies against Ro\u002FSSA and La\u002FSSB will be followed with regard to clinical manifestations and immunological parameters to identify immunological changes, environmental factors, and early clinical symptoms that characterize the progression from serological autoreactivity to clinically manifest disease.",[25],"2024-09-10",{"date":100,"type":47},"2024-09-19",{"date":102,"type":47},"2024-02-09",{"date":104,"type":20},"2038-12",{"name":106,"class":54},"Karolinska Institutet"]